Castleman Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Castleman Disease Market Outlook

Thelansis’s “Castleman Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Castleman Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Castleman Disease Overview

Castleman Disease (CD) encompasses a cluster of infrequent lymphoproliferative conditions involving enlarged lymph nodes displaying distinctive microscopic alterations, an extensive array of inflammatory indications, and laboratory irregularities. It can affect lymph nodes across various bodily regions, simulating non-cancerous and cancerous anomalies, such as those found in the neck, chest, abdomen, and pelvis. From a pathological standpoint, it can be categorized into hyaline vascular type (HV-CD), plasma cell type, mixed type, and Castleman disease associated with human herpesvirus (HHV)-8. On a pathogenic level, the plasma cell variant of Castleman Disease is associated with excess production of IL-6 and heightened expression of IL-6 receptors, triggering the proliferation of B lymphocytes and vasculogenesis, which in turn results in an array of systemic manifestations like fever, anemia, hypoproteinemia, and proteinuria. In some instances of mixed CD, an elevated IL-6 level is also found to promote the generation of hepcidin from the liver, potentially leading to iron-deficiency anemia. There are four primary types of Castleman Disease: unicentric Castleman disease (UCD), localized and possibly affecting one or more enlarged lymph nodes in a specific body region; human herpesvirus 8 associated multicentric Castleman disease (HHV-8-associated MCD); POEMS-associated MCD; and idiopathic multicentric Castleman disease (iMCD), which is widespread and impacts numerous lymph nodes and lymphatic tissues. The idiopathic multicentric Castleman disease (iMCD) can be further categorized into three clinical subgroups:

1. iMCD with TAFRO syndrome (iMCD-TAFRO), characterized by Thrombocytopenia, Anasarca, Fever, Renal dysfunction, or Reticulin fibrosis and Organomegaly.
2. iMCD with idiopathic plasmacytic lymphadenopathy (iMCD-IPL), identified by thrombocytosis, hypergammaglobulinemia, and a more protracted disease trajectory.
3. iMCD, not otherwise specified (iMCD-NOS), diagnosed in iMCD patients devoid of TAFRO syndrome or iMCD-IPL.

Unicentric Castleman Disease demonstrates a highly favorable prognosis. It typically does not advance into lymphoma, and surgical excision of the tumor results in a cure for 90–95% of cases. The prognosis for individuals with Multicentric Castleman Disease varies, contingent upon the precise nature of their ailment. Some patients encounter severe exacerbations that can be life-threatening, whereas others endure more lingering symptoms.

• The historical 5-year overall survival rate has hovered around 65-75%. Around 4,300-5,200 fresh cases of Castleman Disease are diagnosed annually in the United States. Unicentric Castleman disease is more prevalent than multicentric Castleman disease and can manifest in individuals of any age, gender, or ethnicity, affecting both children and adults. It is most frequently observed in younger females.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: